ŌURA’s Post

Pumped to share that ŌURA is partnering with Dexcom. This collaboration brings together Dexcom’s continuous glucose monitoring (CGM) technology with the Oura Ring’s robust suite of insights, spanning sleep, activity, readiness, heart rate variability, temperature trends, and more. Imagine having the power to connect glucose levels with nuanced insights like how restorative your sleep was, how balanced your activity and recovery cycles are, or even how your body responds to stress over time. This partnership has the potential to deliver unprecedented clarity, empowering users with actionable feedback to make real-time, meaningful changes to their health and well-being. Proud to be part of a team that’s redefining the role of wearables in healthcare.

Can we finally bring together the tools people need to reverse the wave of #type2diabetes? Working at Nutrisense, I saw first hand the impact of sleep and physical activity on #bloodglucose and #metabolichealth. Among our users, people with #prediabetes were especially likely to benefit from regulating their sleep and incorporating physical activity into their day. But behavior change is really hard, especially when you don't see the direct impact of each action. This is why I am so excited that ŌURA and Dexcom are partnering to integrate CGM data with the Oura app. This is a huge win for consumers! ŌURA is a best-in-class sleep and fitness tracker, and their app is a joy to use. Dexcom’s continuous glucose monitors are now available over the counter. I have high confidence that Oura can bring all the data together to motivate and sustain behavior change for consumers who can really benefit from lifestyle changes to maintain a healthy metabolism. I’m excited to see where this partnership goes!

Several years ago, I experimented with this concept in a more conventional way, trying to piece together insights from separate platforms. While the experience was clunky and cumbersome, it had a profound impact on my behavior as both an athlete and a professional. During my studies in AI and Digital Business, as well as through capstone projects, I even explored whether there was a business opportunity in this space. This is why I can only applaud the partnership between ŌURA and Dexcom where personalized health and well-being are being democratized and simplified. It’s inspiring to see innovative solutions that leverage data and technology to empower individuals to elevate their health journey and maximize their potential with ease. #PersonalizedHealth #DigitalHealth #AI #WearableTechnology #HealthInnovation #ŌURA #Dexcom #HealthTech #Wellbeing #PerformanceOptimization #DigitalBusiness #AthleteMindset #MYPo #Maximizeyourpotential #healthcare #prevention

This is a big milestone for ŌURA which through a strategic partnership with Dexcom will provide a first-of-its-kind metabolic health management experience. Dexcom also invested $75 million in Oura’s Series D funding, bringing Pura’s valuation to more than $5 billion. A big day for wearables 👀📈

🚀 Big news in the health tech world! ŌURA and Dexcom are joining forces to integrate their cutting-edge technologies, offering users deeper insights into how their activity, sleep, nutrition, and glucose levels all connect by combining ŌURA’s wearable health ring with Dexcom’s continuous glucose monitoring, this collaboration empowers individuals to make data-driven decisions that can have a lasting impact on their health and well-being. Looking forward to seeing how this integration evolves and how it will shape the future of wellness. 🙌#HealthTech #Wearables #GlucoseMonitoring #HolisticHealth #Wellness #Innovation #StartupJourney #FutureOfHealth

Procrastination is the art of keeping up with yesterday. Investing in Boston Scientific Corporation (BSX): Empowering Your Health Savings Account Growth Summary: Boston Scientific Corporation (BSX) is a globally recognized company that specializes in developing, manufacturing, and marketing innovative medical devices across various interventional medical specialties. With its operations divided into MedSurg and Cardiovascular segments, BSX is at the forefront of advancing healthcare and improving patient outcomes. H2: Seize the Opportunity for Health-Driven Investments! 💪💰 Are you ready to supercharge your Health Savings Account (HSA) growth while making a positive impact on people's lives? Investing in Boston Scientific Corporation (BSX) allows you to align your financial goals with the booming healthcare industry. It's time to take action and avoid the Fear of Missing Out! 🚀 With the rising demand for cutting-edge medical technologies, BSX presents a compelling investment opportunity. By allocating funds from your HSA to BSX, you can actively contribute to the development and availability of life-changing medical devices worldwide. Don't miss out on the chance to invest in a company that positively impacts the health and well-being of individuals and their families. 🌍❤️ Hashtags: #hsa #investing #healthcare #health #family #wellness Emojis: 💪💰 🚀 🌍❤️

I am not a Democrat - most Democrat politicians are owned by corporate interests, I am voting Green Party of the United States this election. But Senator Bernie Sanders Campaign Office is right to grill Novo Nordisk's CEO. Novo Nordisk is robbing the American healthcare system blind, hurting patients like my mother-in-law who can not even get Ozempic for its on-label use, and it is being used off-label for weight loss - which actually has been shown to wipe out muscle (this is why patients that lose weight on Ozempic look like skeletons 💀 😢 ). This needs to stop - and I am happy to work with Senator Sanders and Friends of Bernie Sanders if they need additional analytics support. Most people are terrible at healthcare data analytics and use the confusion to keep things as is. We need to all fix this or America will keep losing with its Disease Care system. We need a Health Care system, starting with earlier diagnoses. Exact Sciences and Quest Diagnostics are working hard to deliver earlier Dxs (diagnoses) for all patients so they can receive the right prescriptions (Rxs). Novo Nordisk turns a blind eye to its awful culture & off-label use of its drugs. There are companies like Novo Nordisk (NVO: Denmark), Sanofi (France), GSK (London), and others which are based in Europe or ex-US countries. They game the system, make tons of money off of American taxpayers & veterans, and pay their executives tons of cash they don't deserve. Most biopharma companies have bloated sales forces given that younger doctors prefer the all-digital experience and do not want to spend time talking to sales reps when they could be talking to patients. Specialty sales reps - such as in Oncology - are typically more experienced, intelligent, and are worth the salaries & compensation. Bad ones are not & need to be fired ASAP. A bad sales reprepresentative is a compliance nightmare for any company. General sales reps - such as those that target Primary Care Physicians, Pediatricians, Dermatologists, et cetera, generally are not worth the cash. One of my former bosses, a Chief Commercial Officer in the US, once joined that "Denmark is a small socialist country that does not understand the American healthcare system". On the contrary, I told that boss they do - and this price gouging on Ozempic for the USA versus Denmark & other wealthy countries is ridiculous. Dear Bernie: let me know how I can help! I will email you. I am voting Green Party - perhaps you will join the Green Party & take this on before you retire from the State of Vermont? Cheers, ~Jeff Conroy 🌎 ~~Global HC Analytics LLC, Founder and Biopharma Forecasting Expert. GHCA is a small, private consultancy that supports small biotech companies with offices in the US. We started as a part-time consultancy but are quickly converting to a HealthCare ThinkTank that Engineers New solutions in Data Analytics to identify wasteful spending in the American healthcare system - the Globe's #1 employer.

A Year from Now You May Wish You Had Started Today Investing in Your Health and Wealth with HSA Accounts #hsa #investing #healthcare #health #family #wellness 💰💪📈🏥👨👩👧👦🌿 NovoCure: Q2 Earnings Snapshot NovoCure, a leading oncology company focused on developing innovative cancer treatments, recently released its Q2 earnings report. The results showed strong growth and promising advancements in their groundbreaking therapies. For investors looking to capitalize on the healthcare sector's potential while investing in their future, NovoCure presents an exciting opportunity. 💼💉🚀📊 Q2 Financial Performance: NovoCure reported impressive financial performance in the second quarter of this year. The company's total revenues reached $129.2 million, marking a remarkable 85% increase compared to the same period last year. This substantial revenue growth is attributed to the increased adoption of NovoCure's tumor treating fields (TTF) therapy worldwide. TTF therapy, an FDA-approved treatment method that uses electric fields to disrupt cancer cell division, has gained significant traction among healthcare providers and patients alike. 📈💵💼 Advancements in Innovative Cancer Treatments: NovoCure continues to lead the way in developing innovative cancer treatments that offer hope to patients and incredible investment potential. During the quarter, the company made notable progress in expanding indications for TTF therapy. With ongoing clinical trials and collaborations with renowned medical institutions, NovoCure aims to extend the benefits of TTF therapy to a broader range of cancer types, improving patient outcomes and expanding market opportunities. 🎯💡💪 Investing in NovoCure: Seizing the Opportunity Investors keen on aligning their financial goals with their passion for healthcare and promoting wellness can consider adding NovoCure to their HSA investment portfolio. By investing in NovoCure, not only are you potentially growing your wealth but also contributing to breakthrough cancer treatments that have the potential to save lives. Take action now to avoid the Fear of Missing Out, secure your financial future, and make a positive impact in the world of healthcare. 💰📉👉🏼⏳ #hsa #investing #healthcare #health #family #wellness 🌿💪🚀📈🏥👨👩👧👦

Market Movers Update! Here's your pre-market rundown. ⁣ Top 3 Market Gainers: SCWorx Corp \(WORX\), with a booming +116.33%, reveals its sturdy market stance and innovation in the Technology Services sector. Following closely is Cerence Inc \(CRNC\), marking a remarkable growth of +106.74% in the same sector, strengthening its market leadership and inventiveness. Also from the same sector, Innovid Corp \(CTV\) has witnessed an impressive increase of +85.80%, demonstrating its strong market presence and creativity. ⁣ Top 3 Market Losers: TMT Acquisition Corp \(TMTC\) in the Finance sector has taken a hit, with a noteworthy drop of -65.84%, reflecting market adversities. Perspective Therapeutics Inc \(CATX\), from the Health Technology sector, has seen its stock decline by -51.38%, signifying market volatility. Also encountering a rough patch from the Health Technology sector is Pyxis Oncology Inc \(PYXS\), coping with a decrease of -45.03%, indicative of the rough market conditions. ⁣ For more information, please visit our website: https://lnkd.in/ew885w3r or read our detailed Medium post here: https://lnkd.in/eG5jxZeJ This update is for informational purposes only and does not constitute trading advice. Stay tuned for more insights, and happy trading!Tags: #zimtra #news 📊 #finance 💰 #markets 📈 #tradingupdate #insights 🔍 #stocks #economy 🌍 #investment 💼 #traderlife #marketnews #financialnews

The armamentarium of therapies for patients with multiple myeloma is ever expanding and provides healthcare providers #HCPs with multiple options to help patients. However, despite the rich treatment landscape, patients will often relapse and become refractory to therapeutic classes. #HCPs are thus tasked with devising long-term treatment strategies optimizing use of available therapies that are constantly being informed by new clinical data and real world evidence. Join me as we hear from our global experts at TODAY’s #EHA2024 Industry Sponsored Symposium titled “Individualized Treatment in Early Relapse for Patients with Relapsed/Refractory Multiple Myeloma (MM).”   https://lnkd.in/ekujH9Ve